Product Documentation
[1] Hu Chiding, Observation of Therapeutic Efficacy of rhG-CSF on Aleukocytosis after Chemotherapy for Malignant Tumor [J]. Journal of Jianghan University (Natural Sciences), 2005 (02), 38-39, 52.
[ABSTRACT] Purpose: to observe the therapeutic efficacy of domestically produced recombinant human granulocyte colony-stimulating factor on aleukocytosis caused by cancer chemotherapy, and the adverse reactions thereof. Method: 69 cases of pathologically confirmed malignant tumor were randomly divided into two groups: an observation group of 35 cases and a generic drug group of 34 cases. Hypodermic injection with a dose of rhG-CSF150g/d was used with the observation group for 1 to 5 days. The generic drug group was treated with generic drugs such as leucogen, etc, orally for 7 days successively. The drugs were quitted when the absolute neutrophil count (ANC) rebounded twice to over 5 × 109/L after falling to the minimum. Result: the differences of the average value of the total white cell counts and the ANC averages of the two groups before and after the treatment had statistical significance (P lower than 0.05). Adverse reactions included mild ostalgia, myalgia or fatigue. Conclusion: rhG-CSF has the effects of decelerating the reduction of ANC, shortening the duration of ANC reduction, promoting the recovery of ANC, and reducing the incidence of infectious fever, hence a valuable supplementary drug in cancer chemotherapy.
[2] Chen Jian, Zheng Kaijun,Ye Chunhua, Xia Ronghua, Yang Xiufang, Chen Guochun. Clinical Observation of Chang Le Kang in Treating Infantile Eczema.[J]. Qingdao Medical Journal, 2006 (03), 172-173.
[ABSTRACT] Purpose: to observe the effects of Chang Le Kang, an intestinal micro-ecological formulation, in treating eczema. Method: Chang Le Kang (a double variable bacterial of clostridium butyricum and Bifidobacteria), produced by Shandong Kexing Bioproducts Co. Ltd., was used to treat infantile eczema. Result: Chang Le Kang was effective in treating infantile eczema, and the statistical analysis shows that P was lower than 0.05 after a comparison of the treatment group and the control group. Conclusion: the therapeutic efficacy of Chang Le Kang in treating infantile eczema is affirmed and safe without side effects.
[3] Wang Qingjiu, Liu Yuxia. A Clinical Report on Chang Le Kang in Treating Infantile Antibiotic-associated Diarrhea[J]. Chinese Journal of Microecology, 2003(3), 65.
[4]Xu Hongji, Chen Mandong. Clinical Experience in Adjuvant Therapy of 42 Cases of Infantile Acute Diarrhea Using Chang Le Kang.[J]. Medical Forums in Basic, 2005 (03), 210.
[5] Hou Bingwen, Tu Jianping. Observation of the Effects of Chang Le Kang in Acute Diarrhea in Infants.[J].Chinese Journal of Microecology, 2004 (03), 60.
[ABSTRACT] Purpose: to probe the effects of the intestinal micro-ecological formulation "Chang Le Kang" in treating acute diarrhea in infants, and to reduce the excessive intravenous infusion and the abuse of antibiotics. Method: 180 cases of acute diarrhea in infants were randomly divided into a treatment group and a control group, both groups used the gastrointestinal mucous membrane protective agent, and the treatment group also used the intestinal micro-ecological formulation "Chang Le Kang". The extinction time of the symptoms and physical signs of both groups, the obvious effective rates and the total effective rates were recorded and compared. Result: the extinction time of the stool characters and defecation frequencies of the treatment group were normal, the extinction time of fever and vomiting was significantly shorter than that of the control group, the obvious effective rate of the treatment group was significantly higher than that of the control group, and the total effective rate was 94.5% (87/92) P <001. Conclusion: the intestinal micro-ecological formulation Chang Le Kang, when used to treat acute diarrhea in infants, is not only capable of shortening the course of disease, but also capable of improving the cure rate without any side effects, therefore can be used as a main drug in adjuvant therapy of acute diarrheal disease in infants to reconstruct the protective microflora barrier in intestinal canals.
[6] Han Fang, Wang Hui, Sun Renhua, Xu Geng. The effects of Erythropoietin on Myocardial Damage and Apoptosis Caused by High Dose of Isoprel[J]. Chinese Journal of Emergency Medicine, 2007(05), 487-490.
[ABSTRACT] Purpose: to observe the effects of erythropoietin (EPO) on gene expression which causes myocardial damage and myocardial apoptosis of rats. Method - male Sprague-Dawley(SD) rats were divided into 3 groups, i.e., a control group, an ISO group and an EPO treatment group, and the levels of the serum creatine kinase and CK-MB and the changes of the expression of myocardial caspase-3 and iNOS were tested. Result: the levels of the myocardial enzyme and CK-MB and the expression of caspase-3 and iNOS of the EPO treatment group were significantly reduced lower than those of the EPO group. Conclusion: erythropoietin is capable of significantly reducing myocardial damage caused by isoprel and inhibiting the expression of caspase-3 and iNOS.
[7]Lin Xiaoying, Huang Tao, Li Zhongxin, Li Yuhua, Huang Hua. The effects of erythropoietin (EPO) on Caspase-9 mRNA of Rats after Cerebral Ischemia-reperfusion[J]. Journal of Clinical Neurology, 2005(06), 449-451.
[ABSTRACT] Purpose: to probe into the effects of EPO on the expression of caspase-9 mRNA of rats after cerebral ischemia-reperfusion. Method - global cerebral ischemia-reperfusion models of rats were prepared, which were randomly divided into a cerebral ischemia-reperfusion group (Group A) and an EPO intervention group (Group B), and Group A and Group B were further divided into five subgroups, i.e., a 6hsubgroup, a 12hsubgroup, a 24hsubgroup, a 48h subgroup and a 72h subgroup. All the rats were decapitated with the brains taken out at proper at the corresponding time points, the RT - PCR technique was adopted to test the expression of caspase9 mRNA in rats' cerebral cortex, and a comparison with the control group (Group C) was performed. Result: (1) the expression of caspase9 mRNA of Group A at all the time points is significantly higher than that of Group B and Group C (, P of both is lower than 0.05); (2) the expression of caspase9 mRNA of Group B at the end of 6h, 12h, 24h and 48h was significantly higher than that of Group C (, P of both is lower than 0.05), but the expression at the end of 72h was not significantly different from that of Group C. Conclusion: one of the nerve protective mechanisms of EPO after ischemical reperfusion injury is related to the inhibiting or down regulation of the expression of caspase9 in the apoptosis pathway.
[8] Shan Peiyan, Gao Jing, Ji Yan, Yan Chuanzhu, Tan Dong. The Protective Effects of EPO on the Expression of Cholinergic Neural Fibers in the Vascular Dementia Rat Model[J]. Journal of Shandong University (Health Sciences), 2007 (08), 813-816.
[ABSTRACT] Purpose: to study the protective effects of erythropoietin(EPO) on the expression of cholinergic neural fibers of rats with vascular dementia (VD). Method: the rats were randomly divided into a sham-operation group, a medication group and a model group, with 12 rats in each group. Method: VD rat models were prepared by the "double vascular occlusion plus sodium nitroprussiate depressurization" technique, and VD rats were treated with EPO. Morris water maze test, Nissle staining, acetylcholinesterase (AchE)histochemical staining and AchE activity measurement were adopted to test the effects of EPO on learning and memory, cellular morphology and the expression and activity of AchE. Result: Through a comparison with the sham-operation group and the medication group, it was shown that EPO significantly shortened the escape latency of the rats in the VD model group in the Morris water maze, significantly increased the number of the pyramidal cells and the Nissle bodies in the hippocampal CA1 area, and significantly increased the number of the AchE immunopositive cells and enhanced the activity of AchE (P lower than 0.01, P lower than 0.05). Conclusion: EPO is capable of improving the behavioral performances and the pathological lesion of VD rats, and the mechanism may be related to its protective function of cholinergic nerve fibers.
[9] Liao Aineng, Zhong Hongbin, Jin Zhe, Chen Aiping. A Report on One Case of EPO-induced Pure Red Cell Aplastic Anemia and the Literature Review[J]. Journal of Clinical Rehabilitative Tissue Engineering Research, 2007(07), 1373+1375.
[ABSTRACT] Purpose: the research is aimed at analyzing, diagnosing and treating EPO-induced pure red cell aplastic anemia. The clinical data of one patient with EPO-induced pure red cell aplastic anemia was analyzed retrospectively, based on a review of the literature. Result: the analysis affirmed the diagnosis of pure red cell aplastic anemia caused by EPO, but the treatment was ineffective. Conclusion: EPO-induced pure red cell aplastic anemia is rare, therefore it is necessary to further explore into the disease; and timely bone marrow puncture and the test of EPO antibodies is conducive to the diagnosis.
[10] Zhang Xueping, Lu Jian, Fu Siwu, Xiao Zaiying, Luo Wuying, Meng Xiaoqi. The in vitro Antagonism of Clostridium Butyricum and Bifidobacteria on Pathogenic Entero Becteria[J]. Chinese Journal of Microecology, 2001 (05), 12-14.
[ABSTRACT] Purpose: to probe into the antagonism of clostridium butyricum and infantile bifidobacteria on some pathogenic entero becteria. Method: single bacterial strains and double bacterial strains of clostridium butyricum and infantile Bifidobacteria were mixed up, and then were respectively inoculated with several strains of pathogenic entero becteria in GAM fluid medium for anaerobic culture. The method of the method of plate culture count was used to count the pathogenic entero becteria. Result: the count of pathogenic entero becteria was significantly reduced after the mixed culture. Conclusion: Clostridium butyricum LCL 166 strains and infantile bifidobacteria strain L CL172 strains have the function of significantly inhibiting the growth and reproduction of several strains of pathogenic entero becteria in vitro.
[11] Chen Qing. A Study of Bifidobacteria and Clostridium Butyricum in Combined Treatment of 72 Cases of Infantile Secondary Lactose Intolerance[J]. Tianjin Medicine Journal, 2007 (03), 237.
[ABSTRACT] Purpose: Secondary lactose intolerance is one of the common causes of persistent diarrhea in infants. Breast feeding has to be replaced by cow milk feeding in conventional therapy, which leads to difficulties of families feeding infants with breast milk. Chang Le Kang, which is a living bacteria formulation composed of bifidobacteria and clostridium Butyricum and developed by our department (of Shandong Kexing Bioproducts Co., Ltd.) from June 2002 to October 2005, successfully cured 72 cases of secondary lactose intolerance in infants, and achieved satisfactory effects. The report is as follows.
[12] Liu Manling, Wang Lie, Song Mei, Li Zhankui. A Study of 60 Cases Using Recombinant Human EPO Combined with Ferralium in Prevention and Treatment of Anemia of Prematurity[J]. Shaanxi Medical Journal, 2008(01), 84-86.
[ABSTRACT] Purpose: to observe the treatment efficacy and side effects of recombinant human EPO (rhuEPO) combined with ferralium in prevention and treatment of anemia of prematurity. Method: 114 cases of anemia in premature children were randomly divided into two groups. The rhuEPO treatment was applied with the observation group 8 days after birth, with a dose of 600IU/(kg·week), 3 times of subcutaneous injection each week for a total of six weeks; while the rhuEPO treatment was not applied with the control group. Both groups took oral Fe 6mg/(kg·d) for 4 weeks since the third week, and took oral phytogermine (5mg/kg per day) and folic acid tablets (5mg per day) for 7 days. Routine blood tests, serum ferritin tests and body weight tests were performed with both groups in the 1st, 2nd, 4th, 6th and 8th weeks, and the number of blood transfusion of both groups were counted. Result: the haemoglobin and packed cell volume of both groups of premature infants were reduced gradually, the decrease range of the observation group is lower than that of the control group, and a significant difference was shown between the two groups (P lower than 0.01); the volume of the reticular cells of the observation group was significantly increased after the therapy, suggesting a significant difference from the control group (P lower than 0.01); the volume of serum ferritin of the observation group showed a downtrend after birth, while that of the control group was gradually increased, suggesting a significant difference between the two groups(P lower than 0.05); but the volume of the observation group picked up after the therapy (P higher than 0.05), and the number of cases receiving blood transfusion was few, with a significant difference (P lower than 0.01). Conclusion: rhuEPO combined with ferralium is capable of effectively preventing and curing anemia of prematurity and reducing the number of times of blood transfusion.
[13] Rao Siqing, Liang Yuanqing, He Zhengxian, Liu Guizhen, Xu Qunfang. An Applied Research of Recombinant Human Granulocyte Colony-stimulating Factor and Ferralium in Very Low Birth Weight Infants[J]. Chinese Journal of Neonatology, 2005(04), 148-152.
[ABSTRACT] Purpose: to evaluate the effects of recombinant human granulocyte colony-stimulating factor (rhEPO) and ferralium on blood transfusion of very low birth weight infants (VL-BW) and the effects in preventing anemia of prematurity. Method: 59 premature infants, with the birth weights lower than or equal to 1500g and the gestational ages lower than or equal to 34 weeks, were studied, wherein, rhEPO treatment was used with the 31 cases in the treatment group from the 5th to 7th days after birth (250U/kg·time, subcutaneous injection, twice per week) for 6 weeks, with ferralium and multiplex vitamin supplemented at the same time; the 28 cases in the control group did not use rhEPO or ferralium treatment. The hematological indicators and the volume and frequencies of blood transfusion of both groups were compared. Result: No difference was shown in the gestational ages and birth weight, and the haemoglobin (Hb), the volume and frequencies of hemospasia, complication and the number of days of mechanical ventilation in the 1st week after birth, between the two groups. The number of times and volume of blood transfusion of each patient in the rhEPO treatment group was 0.7 plus or minus 1.0 times/person and 8.4 plus or minus 13.4 ml/kg, while those of the control group were 1.6 plus or minus 1.2 times/person and 20.8 plus or minus 15.9 ml/kg; a comparison showed a significant difference between the two groups (P lower than 0.001). 74.19 percent of the treatment group needs no blood transfusion, while only 32.14 percent of the control needs no blood transfusion (P lower than 0.001). The Hb of both groups was gradually decreased after birth, but the decrease range of the control group was more significant than that of the treatment group (P lower than 0.005); the lowest mean Hb level of the treatment group was (98.5 plus or minus 16.1)g/L, while that of the control group was (84.9 plus or minus 19.3)g/L. The volume of reticular cells of the treatment group was significantly higher than that of the control group (P lower than 0.001) one week after the rhEPO treatment, and reached the peak in the 2nd week.
[14] He Lihong, Chen Aizhen, Wu Lina, Kuang Lusha. The Prevention and Treatment of Anemia of Prematurity Using Recombinant Human Erythropoietin and Long-term Intermittent Fe Supplementation[J]. Chinese Journal of Birth Health and Heredity, 2007(01), 78-80.
[ABSTRACT] Purpose: to probe into the therapeutic efficacy of early use of recombinant human erythropoietin (rHuEPO) and ferralium and late long-term intermittent Fe supplementation in the prevention and treatment of anemia of prematurity, and the effects on the growth, development and intelligence of premature infants. Method: a total of 179 premature infants, accepted by the NICU of our hospital from Feb 2002 to Feb 2005, were randomly divided into a treatment group of 64 cases, a control group of 57 group and a blank group of 58 cases. The treatment group used rHuEPO (from the 1st week after birth, 750 IU.kg-1.w-1, totally 6 weeks) and ferralium (from the 14th day after birth, 2mg.kg-1.d-1 of Fe, totally 6 weeks) and Fe was supplemented once a week since then (2mg.kg-1 of Fe) until the 12 months of age. Both rHuEPO and ferralium were used with both the control group and the treatment group for 6 weeks in the same method after birth, with the supplementation of Fe stopped. The blank group did not use the rHuEPO and ferralium. The changes of the HGB, Serum ferritin (SF), body weights and statures of the three groups of premature infants were observed until the 12 months of age, and DDST intelligence tests were performed at 6 and 12 months of age. Result: HGB of the treatment group and the control group in the 12th week was obviously higher than that of the blank group (P lower than 0.01), HGB of the treatment group and the control group at the four and a half months of age was obviously higher than that of the blank group (P lower than 0.01), SF of the treatment group at the three and a half months of age was obviously higher than that of both the control group and the blank group (P lower than 0.01), the body weights and statures of the treatment group at the six and a half months of age were significantly higher than those of both the control group and the blank group (P lower than 0.01, P lower than 0.05). DDS of the treatment group at six and twelve months of age was significantly higher than that of both the control group and the blank group (P lower than 0.05). Conclusion: the early use of rHuEPO and ferralium with the premature infants after birth can alleviate early anemia in premature infants, continued long-term intermittent supplementation of Fe can effectively prevent and treat the late anemia in and improve the growth and development of premature infants.
[15] Rao Siqing, Wang Lihu, Liang Yuanqing, He Zhengxian, Xu Qunfang. Clinical Observation of Recombinant Human Erythropoietin in Preventing Anemia of Prematurity[J]. Chinese Journal of Practical Pediatrics, 2004(05), 294-296.
[ABSTRACT] Purpose: to evaluate the effects of different doses of recombinant human erythropoietin (rHuEPO) in the prevention anemia of prematurity. Method: 67 premature infants, accepted by the Liwan Hospital of Guangzhou Medical College from 2000 to 2002 and with the gestational ages lower than or equal to 34 weeks and the birth weights lower than or equal to 20kg, were randomly divided into a high-dose group, a low-dose group and a control group. Both the high-dose and the low-dose groups started receive rHuEPO from the 3rd to the 7th day after birth, 500IU/kg and 150IU/kg per week respectively, twice every week, subcutaneous injection, for a total of six weeks; 3- 8mg·kg-1·d-1 oral Fe was used with all the three groups during the treatment period. All the hematological indicators were observed 1-8, 12 and 16 weeks after birth. Result: 16 weeks of research of totally 58 cases of premature infants was completed, the ratio of haemoglobin to packed cell volume of all the three groups were gradually decreased, wherein, the decrease range of the high-dose group was the lowest, and that of the control group was the highest (P of both groups was lower than 0.01); the time points when the ratio of haemoglobin to packed cell volume of both the high-dose and low-dose groups reached the minimum were advanced. The volumes of reticular cells of both the high-dose and low-dose groups were significantly higher than that of the control group after 1 week of rHuEPO treatment, in particular, the volume of the high-dose group was most obviously increased (P lower than 0.01), reaching the peak after 2 to 3 weeks of treatment. The contents of serum iron in all the three groups showed a downtrend, but decrease rate of the treatment group was more obvious than that of the control group during the treatment group (P lower than 0.01). Conclusion: rHuEPO, aided by ferralium, is capable of effectively preventing anemia of prematurity, and a dose of 500IU/kg of rHuEPO per week is more effective than a dose of 15 0IU/kg.